Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247208 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL7749229 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL18101264 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL30896646 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL1246378 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL25124368 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL8072720 | 0.97 | — | — | |
| SCHEMBL5257989 | 0.97 | — | — | |
| SCHEMBL455134 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20767612 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995015983-A1 | PROCESS FOR IMMOBILISING BIOMOLECULES AND AFFINITY LIGANDS ON POLYMER CARRIERS | GLUESENKAMP KARL HEINZ (DE) | 1995-06-15 | — | — | WO | claimed |
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | TECAN SP, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2016160741-A1 | SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY, METHODS, REAGENTS AND KITS | QUANTALYTICAL LABS INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
| EP-0966468-B1 | CROWN ETHER-DERIVATISED PERYLENES | CIBA SC HOLDING AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-6602692-B1 | Reacting a water insoluble matrix having amino groups such as membranes, resins, microtiter plates, with an activating cyclobutene such as 1,2-diethoxycyclobut-1-en-3,4-dione and then incubating with an amino-functional protein | GLUESENKAMP KARL-HEINZ (DE) | 2003-08-05 | — | — | US | disclosed |
| US-6323163-B1 | PERFLUOROPOLYOXYALKYLENE CHAIN HAVING AVERAGE MOLECULAR WEIGHT OF 800 OR MORE, CONTAINING CYCLIC POLYETHER GROUP HAVING AT LEAST 4 OXYGEN ATOMS, ALSO HAVING AMIDE, SULFONAMIDE, ETHER OR ESTER LINKAGE BETWEEN CHAIN AND CYCLIC GROUP | HITACHI, LTD. (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-0966468-A1 | CROWN ETHER-DERIVATISED PERYLENES | Ciba SC Holding AG (CH) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998039333-A1 | CROWN ETHER-DERIVATISED PERYLENES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | CYP2C8, CES2, UGT1A8 | CHRM2 2186/4885CHRM4 1139/4885CHRM5 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.